35Pharma
Julia Schoelermann has extensive experience in business development, investor relations, and project management in the pharmaceutical and biotechnology industry. Julia currently holds leadership positions at 35Pharma and HyperMabs Inc. Julia played a crucial role in the acquisition of Forbius by Bristol Myers Squibb. Additionally, Julia has a strong academic background with a PhD in Biomedicine and multiple degrees in molecular biotechnology and biophysical chemistry.
This person is not in any offices
35Pharma
Biopharmaceutical company that designs and develops biologics for pulmonary hypertension & musculoskeletal disorders.